Taguchi S, Kawai T, Ambe Y, Kishitani K, et al. Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study. Int J Urol 2023;30:1180-1186.
PMID: 37740409